Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | terminated | Phase 1 | 5 | Lioe-Fee de Geus-Oei, MD PhDOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | terminated | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 4 | Mar 13, 2024 | clinicaltrials |
| NCT03533946 | Rucaparib in Nonmetastatic prOstAte With BRCAness(ROAR) | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer | terminated | Phase 1 | 56 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03051516 | HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions | terminated | Phase 4 | 188 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05169372 | Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From Brazil(PET-PSMA) | terminated | — | 12 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT04727736 | 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer | terminated | Phase 2 | 47 | Ashok MuthukrishnanOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02279693 | Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer(PROSTRACK) | terminated | N/A | 3 | Centre Georges Francois LeclercOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03577028 | Study of HPN424 in Patients With Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 104 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Feb 14, 2024 | clinicaltrials |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 16 | THERAPIM PTY LTDINDUSTRY | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02995330 | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | terminated | Phase 3 | 23 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent(VERACITY) | terminated | Phase 3 | 105 | Veru Inc.INDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT02478502 | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | terminated | Phase 2 | 14 | University Hospital, AkershusOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT04264208 | HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer | terminated | Phase 2 | 4 | Andrei IagaruOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01996696 | Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate(PREMIUM) | terminated | Phase 2 | 83 | AHS Cancer Control AlbertaOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02735109 | Interest of the Confocal Microscope in the Diagnosis of Epidermoid Carcinoma of the Vulva and Their Precursors | terminated | N/A | 10 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 8 | Accutar Biotechnology IncINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04234399 | Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy | terminated | — | 22 | University of VermontOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | terminated | N/A | 52 | University of WashingtonOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05124795 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 18 | Immunic AGINDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04528199 | [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer | terminated | Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer | terminated | Phase 2 / Phase 3 | 46 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT03858166 | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer | terminated | Phase 4 | 68 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | terminated | Phase 3 | 74 | Chinese University of Hong KongOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | terminated | Phase 3 | 38 | Frederick R. Ueland, M.D.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04999605 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 8 | AkesoINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT00176631 | Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT00633087 | A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer(2-Deoxyglucose) | terminated | Phase 1 / Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04267939 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | terminated | Phase 1 | 14 | BayerINDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03837353 | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | terminated | Phase 1 / Phase 2 | 18 | NYU Langone HealthOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04033328 | Study of ORIC-101 in Combination With Enzalutamide | terminated | Phase 1 | 41 | ORIC PharmaceuticalsINDUSTRY | 1 | Dec 15, 2023 | clinicaltrials |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | terminated | Phase 1 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | terminated | N/A | 64 | University of WashingtonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | terminated | Early Phase 1 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab | terminated | N/A | 1 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03550040 | 3D Versus Robot Assisted Laparoscopic Prostatectomy. | terminated | N/A | 155 | Tampere University HospitalOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03944902 | CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients(BRCA) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Nov 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2024source: clinicaltrials